Pre – | FU - | Time-by-group effect | Pre-FU ES | |
---|---|---|---|---|
ST | 6.33 (0.75) | 1.74 (2.31) | ||
PT | 6.09 (1.07) | 1.59 (2.49) | ||
ST | 4.60 (1.32) | 1.37 (1.22) | ||
PT | 5.32 (0.95) | 1.28 (1.32) | ||
ST | 41.57 (16.93) | 20.91 (12.95) | ||
PT | 39.16 (18.06) | 16.70 (13.23) | ||
ST | 43.72 (14.98) | 21.72 (11.53) | ||
PT | 38.91 (15.79) | 19.79 (13.61) | ||
ST | 38.18 (15.33) | 18.70 (12.55) | ||
PT | 37.15 (13.80) | 18.72 (10.63) | ||
ST | 15.10 (8.09) | 8.50 (8.21) | ||
PT | 11.90 (7.35) | 5.79 (6.07) | ||
ST | 19.65 (6.80) | 10.13 (7.09) | ||
PT | 17.78 (7.20) | 8.80 (7.75) | ||
ST | 18.51 (6.93) | 8.83 (6.67) | ||
PT | 16.05 (6.84) | 10.00 (7.85) | ||
ST | 13.13 (5.72) | 6.39 (5.12) | ||
PT | 11.07 (6.91) | 5.68 (6.83) | ||
ST | 10.16 (5.65) | 5.27 (5.10) | ||
PT | 7.85 (6.09) | 4.65 (4.77) |
SCAS Youth | SCAS-P Mother | SCAS-P Father | |||||||
---|---|---|---|---|---|---|---|---|---|
ST ( | PT ( | Fisher’s | ST ( | PT ( | Fisher’s | ST ( | PT ( | Fisher’s | |
Over clinical cut-off | 75.9% (41) | 67.9% (38) | 90.7% (49) | 85.7% (48) | 78.4% (40) | 84.9% (45) | |||
RC deterioration | 0% (0) | 0% (0) | - | 0% (0) | 0% (0) | - | 0% (0) | 1.9% (1) | |
RC improvement | 63.0% (34) | 67.9% (38) | 81.5% (44) | 69.6% (39) | 74.5% (38) | 71.7% (38) | |||
RC but not CSC | 18.5% (10) | 19.6% (11) | 33.3% (18) | 12.5% (7) | 17.6% (9) | 32.1% (17) | |||
CSC | 44.4% (24) | 48.2% (27) | 48.1% (26) | 57.1% (32) | 56.9% (29) | 41.5% (22) | |||
RC deterioration | 0% (0) | 5.4% (3) | 5.6% (3) | 10.7% (6) | 7.8% (4) | 5.7% (3) | |||
RC improvement | 63.0% (34) | 50.0% (28) | 77.8% (42) | 66.1% (37) | 66.7% (34) | 56.6% (30) | |||
RC but not CSC | 3.7% (2) | 19.6% (11) | 14.8% (8) | 28.6% (16) | 21.6% (11) | 15.1% (8) | |||
CSC | 59.3% (32) | 35.7% (20) | 68.5% (37) | 48.2% (27) | 52.9% (27) | 47.2% (25) |
ST group ( | PT group ( | Fischer’s | |
---|---|---|---|
Post-treatment | |||
Primary diagnosis | 50.0% (27) | 66.1% (37) | |
All diagnosis | 25.9% (14) | 48.2% (27) | |
Primary diagnosis | 74.1% (40) | 76.8% (43) | |
All diagnosis | 46.3% (25) | 58.9% (33) |
Youths in ST group ( | Youths in PT group ( | |
---|---|---|
Mean age in years (SD) | 10.18 (1.46) | 11.82 (2.49) |
Males (%) | 32 (59.3) | 25 (44.6) |
On psychopharmacological medication | 3 (6.7) | 2 (4.5) |
Primary diagnosis (%) | ||
SAD | 24 (44.4) | 15 (26.8) |
GAD | 15 (27.8) | 14 (25.0) |
SoP | 7 (13.0) | 7 (12.5) |
SP | 6 (11.1) | 12 (21.4) |
OCD | 1 (1.9) | 4 (7.1) |
AP without PD | 1 (1.9) | 4 (7.1) |
CSR mean for primary diagnosis | 6.33 (0.75) | 6.09 (1.07) |
CSR mean for all diagnosis | 4.60 (1.33) | 5.32 (0.95) |
Comorbid diagnoses (%) | ||
Anxiety disorders | 50 (92.6) | 47 (83.9) |
Externalizing disorders | 6 (11.2) | 6 (10.7) |
Mood disorder | 1 (1.9) | 4 (7.1) |
Other | 4 | 3 |
No comorbidity | 4 (7.4) | 9 (16.1) |
Number of anxiety disorders per youth ( | 2.36 | 2.10 |
Pre – | Post – | Time-by-group effect | Pre-post ES | |
---|---|---|---|---|
ST | 6.33 (0.75) | 2.85 (2.41) | ||
PT | 6.09 (1.07) | 2.16 (2.59) | ||
ST | 4.60 (1.32) | 2.13 (1.36) | ||
PT | 5.32 (0.95) | 1.69 (1.53) | ||
ST | 41.57 (16.93) | 24.13 (14.36) | ||
PT | 39.16 (18.06) | 21.57 (14.42) | ||
ST | 43.72 (14.98) | 23.76 (11.90) | ||
PT | 38.91 (15.79) | 22.25 (12.59) | ||
ST | 38.18 (15.33) | 22.55 (12.57) | ||
PT | 37.15 (13.80) | 23.56 (13.87) | ||
ST | 15.10 (8.09) | 7.57 (6.40) | ||
PT | 11.90 (7.35) | 7.55 (6.46) | ||
ST | 19.65 (6.80) | 12.06 (7.28) | ||
PT | 17.78 (7.20) | 10.61 (7.28) | ||
ST | 18.51 (6.93) | 11.90 (6.29) | ||
PT | 16.05 (6.84) | 10.96 (7.72) | ||
ST | 13.13 (5.72) | 7.26 (5.66) | ||
PT | 11.07 (6.91) | 6.82 (6.28) | ||
ST | 10.16 (5.65) | 6.86 (4.63) | ||
PT | 7.85 (6.09) | 5.71 (5.46) |